Castle Biosciences is a commercial-stage dermatological cancer company focused on providing physicians and their patients with genomic information to make treatment decisions. Co.'s main product, DecisionDx®-Melanoma, is a multi-gene expression profile (GEP) test that predicts the risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer. Co. has commercially launched its cutaneous squamous cell carcinoma GEP test, DecisionDx®-SCC, and its GEP test for suspicious pigmented lesions, DecisionDx® DiffDx-Melanoma. Co. also markets DecisionDx®-UM, which is a GEP test that predicts the risk of metastasis for patients with uveal melanoma. The CSTL stock yearly return is shown above.
The yearly return on the CSTL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CSTL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|